The healthcare investment landscape is witnessing unprecedented opportunities in the HER2-low cancer therapeutic space, driven by scientific breakthroughs and expanding market potential. This emerging sector represents a convergence of cutting-edge medical research, innovative drug development, and substantial commercial opportunities that are reshaping the oncology market. The HER2 Low Cancers Market has evolved from a niche Read.